Candriam SCA’s Applied Therapeutics APLT Stock Holding History

Candriam SCA’s Portfolio APLT Stock Details APLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-80,000	Closed	-$2.89M	–	804
2020 Q2	$2.89M	Buy	+80,000	New	+$3.35M	0.03%	429

Other funds holding APLT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Candriam SCA's APLT Position: Q3 2020 in Review

Candriam SCA sold out of Applied Therapeutics (APLT) in Q3 2020, closing a stake of 80,000 shares — an estimated $2.89M sold.

Candriam SCA first reported a position in APLT in Q2 2020 and held it in 1 quarter. The position peaked at $2.89M in Q2 2020. 66 funds tracked by Wall St. Rank hold APLT as of Q3 2020.

Candriam SCA reported no remaining Applied Therapeutics position as of Q3 2020 after selling out during the quarter.
Candriam SCA sold 80,000 Applied Therapeutics shares in Q3 2020, an estimated $2.89M.
Candriam SCA first reported a position in Applied Therapeutics in Q2 2020 and held it in 1 quarter.
Candriam SCA's Applied Therapeutics position peaked at $2.89M in Q2 2020.
66 funds tracked by Wall St. Rank held Applied Therapeutics as of Q3 2020.

Based on Candriam SCA's 13F filing for Q3 2020, filed 19 Oct 2020.